Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection

REFERENCES

• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
   PubMed Web of Science ®Google Scholar
• Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011;91:1279–1285.
   PubMed Web of Science ®Google Scholar
• Silva MF, Sapisochin G, Strasser SI, et al. Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: a multicenter, exploratory analysis. Eur J Surg Oncol. 2013;39:386–395.
   PubMed Web of Science ®Google Scholar
• Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–510.
   PubMed Web of Science ®Google Scholar
• Jin J, Zhu P, Liao Y, et al. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget 2015;6:19217–1927.
   PubMed Web of Science ®Google Scholar
• Goh BK, Teo JY, Chan CY, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system. J Surg Oncol. 2016;113:89–93.
   PubMed Web of Science ®Google Scholar
• Tan N, Liu Q, Liu X, et al. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathology 2016;68:221–229.
   PubMed Web of Science ®Google Scholar
• Fang F, Chang RM, Yu L, et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63:874–885.
   PubMed Web of Science ®Google Scholar
• Yan TH, Yang H, Jiang JH, et al. Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:4126–4131.
   PubMed Web of Science ®Google Scholar
• Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143:1050–1054.
   PubMed Web of Science ®Google Scholar
• Yuan RH, Lai HS, Hsu HC, et al. Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma. J Gastrointest Surg. 2014;18:1784–1794.
   PubMed Web of Science ®Google Scholar
• Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686–692.
   PubMed Web of Science ®Google Scholar
• Kumagai I, Masuda T, Sato S, et al. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern. Hepatol Res. 2001;20:312–319.
   PubMed Web of Science ®Google Scholar
• Mondada D, Bosman FT, Fontolliet C, et al. Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival. Virchows Arch. 2006;448:35–45.
   PubMed Web of Science ®Google Scholar
• Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: Predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850–3859.
   PubMed Web of Science ®Google Scholar
• Xiang ZL, Zeng ZC, Tang ZY, et al. Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol Rep. 2011;38:3531–3539.
   PubMed Web of Science ®Google Scholar
• Lu XY, Xi T, Lau WY, et al. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol. 2011;18:2210–2217.
   PubMed Web of Science ®Google Scholar
• Chan AW, Tong JH, Chan SL, et al. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 2014;64:935–950.
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503.
   PubMed Web of Science ®Google Scholar
• Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114.
   PubMed Web of Science ®Google Scholar
• Kumagai A, Kondo F, Sano K, et al. Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: Relationship with tumor size and cell differentiation. J Hepatobiliary Pancreat Sci. 2016;23:414–421.
   PubMed Web of Science ®Google Scholar
• Pang YB, Zhong JH, Luo XL, et al. Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi. Tumour Biol. 2016;37:5879–5884.
   PubMed Web of Science ®Google Scholar
• Yoneda N, Sato Y, Kitao A, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest. 2011;91:262–272.
   PubMed Web of Science ®Google Scholar
• Yuan RH, Jeng YM, Hu RH, et al. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 2011;15:321–329.
   PubMed Web of Science ®Google Scholar
• Feng J, Zhu R, Chang C, et al. CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection. PLoS One. 2016;11:e0151501.
   PubMed Web of Science ®Google Scholar